Alecensa (alectinib) — United Healthcare
Soft Tissue Sarcoma / Uterine Neoplasms - Inflammatory Myofibroblastic Tumor (IMT)
Initial criteria
- Diagnosis of inflammatory myofibroblastic tumor (IMT)
- Presence of ALK translocation
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Alecensa therapy
Approval duration
12 months